JP2004515202A - アグリコ生成物及び利用法 - Google Patents

アグリコ生成物及び利用法 Download PDF

Info

Publication number
JP2004515202A
JP2004515202A JP2000571873A JP2000571873A JP2004515202A JP 2004515202 A JP2004515202 A JP 2004515202A JP 2000571873 A JP2000571873 A JP 2000571873A JP 2000571873 A JP2000571873 A JP 2000571873A JP 2004515202 A JP2004515202 A JP 2004515202A
Authority
JP
Japan
Prior art keywords
peptide
patient
antibody
blood
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000571873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004515202A5 (enExample
Inventor
ボゴーク，サミュエル
エス． ボゴーク，エレノア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2004515202A publication Critical patent/JP2004515202A/ja
Publication of JP2004515202A5 publication Critical patent/JP2004515202A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Jellies, Jams, And Syrups (AREA)
JP2000571873A 1998-09-04 1999-08-30 アグリコ生成物及び利用法 Withdrawn JP2004515202A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/146,755 US6242578B1 (en) 1994-02-17 1998-09-04 Aglyco products and methods of use
PCT/US1999/019836 WO2000018351A2 (en) 1998-09-04 1999-08-30 Aglyco products and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010263994A Division JP2011087589A (ja) 1998-09-04 2010-11-26 アグリコ生成物及び利用法

Publications (2)

Publication Number Publication Date
JP2004515202A true JP2004515202A (ja) 2004-05-27
JP2004515202A5 JP2004515202A5 (enExample) 2010-04-22

Family

ID=22518867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000571873A Withdrawn JP2004515202A (ja) 1998-09-04 1999-08-30 アグリコ生成物及び利用法
JP2010263994A Pending JP2011087589A (ja) 1998-09-04 2010-11-26 アグリコ生成物及び利用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010263994A Pending JP2011087589A (ja) 1998-09-04 2010-11-26 アグリコ生成物及び利用法

Country Status (13)

Country Link
US (4) US6242578B1 (enExample)
EP (2) EP1990058A1 (enExample)
JP (2) JP2004515202A (enExample)
KR (1) KR100451446B1 (enExample)
CN (2) CN101096382A (enExample)
AT (1) ATE406175T1 (enExample)
AU (1) AU771836B2 (enExample)
BR (1) BR9913446A (enExample)
CA (1) CA2341763C (enExample)
DE (1) DE69939430D1 (enExample)
IL (3) IL141775A0 (enExample)
NZ (4) NZ533511A (enExample)
WO (1) WO2000018351A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176275B2 (en) * 1998-09-04 2007-02-13 Samuel Bogoch Anthrax and small pox replikins and methods of use
DE10034712A1 (de) * 2000-07-17 2002-02-07 Arimedes Biotechnology Gmbh Verbrückte Glykokonjugate
US7189800B2 (en) 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7894999B2 (en) 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
JP2004535171A (ja) 2001-03-27 2004-11-25 ボゴーク，サミュエル レプリキンペプチドおよびその使用
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7442761B2 (en) 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
NZ592340A (en) * 2001-03-27 2012-12-21 Elenore S Bogoch A method for making a virus vaccine compising Replikin peptides
WO2003005880A2 (en) 2001-07-09 2003-01-23 Samuel Bogoch Replikin peptides and uses thereof
KR101067654B1 (ko) * 2001-07-09 2011-09-26 엘레노어 에스 보고치 레플리킨 펩타이드 및 그의 이용
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
US8603345B2 (en) * 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US9254315B2 (en) 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US9002652B1 (en) * 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
WO2006088962A2 (en) 2005-02-16 2006-08-24 Samuel Bogoch Replikin peptides and uses thereof
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
JP2006288670A (ja) * 2005-04-11 2006-10-26 Terumo Corp カテーテル
EP2092059A4 (en) * 2006-10-24 2012-03-28 Bogoch Samuel METHOD FOR FORECASTING INFLUENZA EXCESSIONS BY CORRELATION OF AN INCREASED REPLICINE MIRROR IN WHITE SPOT AND / OR TAURA VIRUSES IN CRABES
US20090017052A1 (en) * 2007-01-18 2009-01-15 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
US20100105634A1 (en) * 2007-03-07 2010-04-29 Cargill, Incorporated Use of glucosamine as a mental and physical stress recovery enhancer and a performance enhancer
MX2009013091A (es) * 2007-05-30 2010-07-30 Bogoch Samuel Peptidos de repliquina sinteticos contra infeccion patogenica de invertebrados en acuicultura.
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
CA2842345A1 (en) 2011-07-20 2013-01-24 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032106A1 (en) * 1995-04-11 1996-10-17 Samuel Bogoch Aglyco products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298590A (en) * 1975-02-25 1981-11-03 Samuel Bogoch Detection of malignant tumor cells
US4840915A (en) * 1975-02-25 1989-06-20 Brain Research, Inc. Method for diagnosing malignant tumors
US4041146A (en) * 1975-05-01 1977-08-09 General Electric Company Method for detection of biological particles
US4486538A (en) * 1978-07-07 1984-12-04 Samuel Bogoch Detection of malignant tumor cells
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032106A1 (en) * 1995-04-11 1996-10-17 Samuel Bogoch Aglyco products

Also Published As

Publication number Publication date
AU5698699A (en) 2000-04-17
CA2341763A1 (en) 2000-04-06
EP1990058A1 (en) 2008-11-12
CN1324258A (zh) 2001-11-28
KR20010072517A (ko) 2001-07-31
NZ544362A (en) 2008-05-30
US6638505B2 (en) 2003-10-28
IL192679A0 (en) 2009-02-11
US20040077532A1 (en) 2004-04-22
ATE406175T1 (de) 2008-09-15
CA2341763C (en) 2014-01-21
DE69939430D1 (de) 2008-10-09
WO2000018351A3 (en) 2000-07-13
BR9913446A (pt) 2004-03-02
IL192679A (en) 2011-10-31
EP1115418A4 (en) 2004-06-09
US20030023047A1 (en) 2003-01-30
IL141775A (en) 2008-11-26
CN1328286C (zh) 2007-07-25
WO2000018351A2 (en) 2000-04-06
US20080241859A1 (en) 2008-10-02
AU771836B2 (en) 2004-04-01
NZ556151A (en) 2009-03-31
JP2011087589A (ja) 2011-05-06
KR100451446B1 (ko) 2004-10-06
CN101096382A (zh) 2008-01-02
NZ533511A (en) 2006-08-31
US7381411B2 (en) 2008-06-03
EP1115418A2 (en) 2001-07-18
EP1115418B1 (en) 2008-08-27
NZ510921A (en) 2004-09-24
US6242578B1 (en) 2001-06-05
IL141775A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
JP2011087589A (ja) アグリコ生成物及び利用法
EP0698091B1 (en) Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
Young et al. Invasive aspergillosis: absence of detectable antibody response
JP2004515202A5 (enExample)
WO2021233885A1 (en) Mimotope peptides of the spike protein from the sars-cov-2 virus
JPH01502194A (ja) 肝細胞内で亜三日熱マラリヤ原虫により生成されたタンパク質の特微的なエピトープを単数又は複数有する少なくとも１つのペプチド配列を含む分子、及びこれらの分子を含む化合物
Wetter et al. Differences in outer membrane characteristics between gallstone-associated bacteria and normal bacterial flora
EP0812191B1 (en) Peptides for the treatment of cancer
Garred et al. A low serum concentration of mannan‐binding protein is not associated with serogroup B or C meningococcal disease
CN102504016B (zh) 淀粉样蛋白纤维性寡聚体构象型抗原表位多肽及其应用
JP2886979B2 (ja) タンパク質複合体
US20240132576A1 (en) Coronavirus: early detection and treatment
TWI763714B (zh) 緩解發炎之tn疫苗及方法
RU2403869C1 (ru) Способ определения специфического поражения печени у больных лепрой
CH694905A5 (it) Peptidi derivati dalla proteina HMGB1 per l'immunoterapia attiva nell'infiammazione sistematica letale.
BG64056B1 (bg) Състави и методи за откриване и лечение на спин
COHEN P2A) and'7s y-globulin'as defined by imuno
Barakat Doppler us imaging findings in children with idiopathic portal vein cavernous deformity presenting with variceal haemorrhage
Gmiński et al. Cross immunoreactivity of aortic kappa-2-elastin with some antibacterial antisera
JPH02157298A (ja) 新規補体制御物質
HK1011710B (en) Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091214

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101126

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110121

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120814

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121206